Director Parsons buys 10,000 shares of ONCY at $1.03; holdings rise 31.4% to 41,849 shares.
Director James T. Parsons purchased 10,000 shares at $1.03 on 2026-03-11, increasing his shareholding by 31.4% from 31,849 to 41,849 shares and committing $10,300.00 to the position. The purchase occurred at a price 5.1% above the current market price of $0.98 and 27.5% below the 52-week high of $1.42, placing the transaction in the middle range of recent price action. The stock has declined 31.0% from its 52-week high but recovered 14.8% over the prior 30 days, suggesting recent volatility and intra-range positioning rather than a clear directional conviction signal. Without context on the director's historical trading patterns or any specific catalyst, the substantial increase in holding concentration warrants observation of whether this represents a discretionary accumulation decision or follows a scheduled plan.
CEO Kelly Jared buys 5,050 shares of ONCY at $0.96; third purchase in 30 days as stock recovers +14.8% in 30 days from near-lows.
Kelly Jared, ONCY's CEO, purchased 5,050 shares at $0.96 on 2026-03-12, marking his third consecutive buy in roughly a month (prior buys on 2026-02-12 and 2026-02-11). The stock is currently trading at $0.98, up 14.8% over the 30-day period, though still down 31.0% from its 52-week high of $1.42 and well above the 52-week low of $0.33. His holdings now stand at 114,050 shares post-transaction. The repeated buying pattern at depressed valuations in a micro-cap ($78.4M market cap) warrants attention, but measurable outcomes for these recent purchases remain limited—his prior trade at this ticker on 2026-02-11 shows a 30-day return of +17.7%, though the 90-day horizon is not yet assessable. Investors should monitor whether this accumulation reflects founder confidence or merely discretionary capital deployment in a volatile micro-cap.
Chief Business Officer Aromando Andrew bought 29,600 shares of ONCY at $0.86; 8 other insiders also bought within 14 days
Aromando Andrew, Chief Business Officer, purchased 29,600 shares at $0.86 on 2026-02-11, increasing his holdings from 25,500 to 55,100 shares (+116.1%). The transaction occurs within a cluster pattern: 8 other insiders also bought within the past 14 days. This coordinated buying activity across multiple executives suggests alignment on company direction at a time when the stock trades at $1.06, down -25.4% from its 52-week high of $1.42. The concentration of insider purchases over a compressed timeframe is a material signal of insider positioning, particularly given the executive role and the aggregate scale of the cohort activity.
Director Deborah Brown buys 25,000 shares at $0.85; 8 other insiders bought within 14 days
Deborah Brown (Director) purchased 25,000 shares at $0.85 on 2026-02-12, increasing her holdings by 29.5% to 109,851 shares. This transaction is part of a broader cluster pattern: 8 other insiders also bought within the past 14 days. The purchase occurs at a price $0.21 below the current market price of $1.06, and the stock is currently trading 25.4% below its 52-week high of $1.42. The concentrated insider accumulation across multiple board/management members within a short window suggests aligned perspectives on current valuation, though the stock's recent positive momentum (1.0% gain over 30 days, 1.9% over 90 days) does not reveal a dramatic reversal signal. Investors should monitor whether this cluster activity continues or whether it marks a turning point in the company's trajectory.
VP Product Development Hagerman buys 10,000 ONCY shares at $0.83; 8 other insiders bought within 14 days (cluster)
Hagerman Allison, VP of Product Development, purchased 10,000 shares at $0.83 on 2026-02-12, increasing her holdings to 115,059 shares. This transaction is notable because it is part of a broader pattern: 8 other insiders also bought within the past 14 days, indicating a cluster buy. The timing occurs while the stock trades at $1.06, approximately 25.4% below its 52-week high of $1.42, potentially reflecting a period of valuation repricing. The clustering of insider purchases across multiple executives warrants investor attention as a signal of internal conviction at current price levels, though the stock's modest 30-day and 90-day gains (+1.0% and +1.9% respectively) suggest modest near-term momentum.
CMO of ONCY buys 12,132 shares at $0.83; 8 other insiders bought within 14 days—coordinated pattern
Heineman Thomas Charles, Chief Medical Officer of Oncolytics Biotech, purchased 12,132 shares at $0.83, expanding his stake by 4.5% to 282,818 shares. The transaction occurred at a notable discount to the current price of $1.06 and well below the 52-week high of $1.42. The timing is material because this purchase is part of a cluster pattern: 8 other insiders also bought within the past 14 days. Cluster buying by multiple executives can signal shared conviction about near-term value, though it may also reflect access to material information or coordinated capital deployment decisions. The stock remains -25.4% from its 52-week high despite recent upward momentum (+1.9% over 90 days), warranting investor attention to underlying catalysts and insider motive.
CFO Kirk buys 12,000 ONCY shares at $0.84; 8 other insiders also bought within 14 days—cluster pattern
Look Kirk, CFO of Oncolytics Biotech, purchased 12,000 shares at $0.84 on 2026-02-12, increasing his holdings from 275,515 to 287,515 shares. This transaction occurs within a broader cluster of insider buying activity: 8 other insiders also purchased shares within the past 14 days. Such coordinated buying by multiple company officers typically reflects management's assessment of current valuation relative to company fundamentals and forward prospects. The stock is currently trading at $1.06, approximately 25.4% below its 52-week high of $1.42, and has been relatively flat over 30 and 90 days (up 1.0% and 1.9% respectively), suggesting the purchases may occur during a period of near-term price consolidation.
Director Pisano buys 30,000 shares at $0.84; 8 other insiders bought within 14 days (cluster pattern)
Director Wayne Pisano purchased 30,000 shares at $0.84 on 2026-02-12, expanding his holdings by 6.5% to 492,414 shares total. The transaction occurred at a notably depressed price—$0.84 is 25.4% below the 52-week high of $1.42 and the current price of $1.06. Most significantly, this buy is part of a broader cluster pattern: 8 other insiders also purchased shares within the past 14 days, suggesting coordinated or independently arrived-at conviction at current levels. Pisano's cross-ticker track record shows an average 30-day return of +19.3% on his prior open-market buys, though that is not ONCY-specific. The cluster buy activity in a micro-cap company (market cap $84.8M) during a period of downward price movement warrants attention to what insiders may be signaling about valuation or near-term catalysts.
Director Seizinger Bernd R. purchases 100,000 shares at $0.83–$0.85 for $83,454; 8 other insiders also bought within 14 days.
Seizinger Bernd R., a Director at Oncolytics Biotech, completed 2 separate purchases totaling 100,000 shares for $83,454.00 between 2026-02-11 and 2026-02-12 at blended average price $0.83, increasing his holdings by 21.4% to 567.0K shares. Notably, 8 other insiders also bought ONCY within the same 14-day window, forming a cluster buy pattern that suggests coordinated conviction at the current price levels. His cross-ticker track record shows an 80.00% win rate over 90-day holds with average 90d return of +415.4%, though this is his second ONCY purchase in recent weeks (prior buy 2026-01-16) and same-ticker outcome metrics are not yet measurable. The stock currently trades at $1.06, down 25.4% from its 52-week high of $1.42, and the insider's entry at $0.83 represents a price level below the recent average, occurring in a micro-cap with market cap of $84.8M.
CEO Kelly Jared purchases 35,100 shares at $0.84 in 2 transactions; 8 other insiders also bought within 14 days
Kelly Jared, CEO of Oncolytics Biotech, executed 2 separate purchases totaling 35,100 shares for $29,520.60, expanding his holdings by 47.5% from 73,900 to 109,000 shares. The transaction price of $0.84 per share is positioned 20.8% below the current price of $1.06 and near the 52-week low of $0.33, suggesting accumulation during a depressed period in the stock's recent range. The cluster pattern—8 other insiders also buying within the past 14 days—indicates coordinated insider confidence rather than isolated trading activity. This multi-insider buying at uniformly low prices warrants investor attention to the underlying fundamentals and near-term catalysts that may have triggered the synchronized accumulation.
Add ONCY to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.
